Preclinical characterization and phase I results of TQB2102, a first-in-class HER2 biparatopic antibody-drug conjugate, in patients with advanced solid tumors.

DOI:10.1016/j.annonc.2026.05.003
作者：D Y Ruan,?S Y Lin,?J J Huang,?Y H Li,?N Li,?X J Qu,?X B Du,?Y M Yin,?Z Y Yuan,?Y X Shi,?F Xu,?X An,?R X Hong,?W Xia,?C Xue,?X W Bi,?K K Jiang,?Q F Zheng,?Y Q Zhang,?J J Peng,?Z Y Liu,?H H Xiong,?A L S
文献类型：期刊论文
补充材料：仅需补充材料